Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,906 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $38.66, for a total transaction of $73,685.96. Following the transaction, the insider now directly owns 1,906 shares of the company’s stock, valued at $73,685.96. The sale was disclosed in a document filed with the SEC, which is available through this link.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) traded down $0.92 during mid-day trading on Wednesday, reaching $35.36. 317,370 shares of the company’s stock traded hands, compared to its average volume of 354,939. Aimmune Therapeutics, Inc. has a 12-month low of $15.97 and a 12-month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts anticipate that Aimmune Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

AIMT has been the subject of a number of recent research reports. Roth Capital initiated coverage on shares of Aimmune Therapeutics in a research note on Monday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Wednesday, November 8th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Saturday, October 21st. Wedbush reissued an “ourperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Finally, Credit Suisse Group raised their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $53.80.

Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its holdings in shares of Aimmune Therapeutics by 3,092.5% in the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after purchasing an additional 542,111 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Aimmune Therapeutics by 30.5% in the 1st quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after purchasing an additional 513,803 shares during the last quarter. State Street Corp boosted its holdings in shares of Aimmune Therapeutics by 49.1% in the 1st quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after purchasing an additional 282,744 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in shares of Aimmune Therapeutics by 6.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock valued at $46,674,000 after purchasing an additional 135,374 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after purchasing an additional 132,603 shares during the last quarter. 73.34% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/06/douglas-t-sheehy-sells-1906-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.